AXIM Starts Phase 2 IBS Trial of CanChew Plus Cannabinoid-based Gum

AXIM Starts Phase 2 IBS Trial of CanChew Plus Cannabinoid-based Gum
AXIM Biotechnologies has enrolled 40 patients with irritable bowel syndrome (IBS) and initiated a Phase 2 clinical trial evaluating the effectiveness of its CanChew Plus cannabinoid (CBD)-based chewing gum for alleviating IBS symptoms. The announcement was made by Medical Marijuana, a U.S. publicly traded cannabis company. The eight-week randomized, double-blind, placebo-controlled clinical trial (NCT03003260) will

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *